<DOC>
	<DOCNO>NCT00119639</DOCNO>
	<brief_summary>This 400 mg ( 2 x 200 mg tablet ) sorafenib single dose , open-label study conduct compare pharmacokinetics plasma urine safety sorafenib subject severe , moderate , mild renal impairment exhibit normal renal function .</brief_summary>
	<brief_title>Study Evaluate Effect Renal Function Single-Dose Pharmacokinetics BAY 43-9006</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Post menopausal female Surgically sterile female Body Mass Index 1837 Subjects Clcr great 80 mL/min Subjects Clcr 50 80 mL/min Subjects Clcr 30 50 mL/min Clcr le 30 mL/min dialysis Subjects must test negative HIV Subjects must test negative drug abuse screen All Subjects : Concomitant Medication : Treatment CYP3A4 inducer , rifampin St. John 's Wort within 14 day Day 1 leave clinic Day 7 Donation blood within 30 day Day 1 Recent participation investigational drug study active medication give within 30 day Day 1 History gastrointestinal disorder could result incomplete absorption study drug Malignancy Significant neurologic psychiatric disorder History drug alcohol abuse year prior screen trial , current intake &gt; 14 standard alcoholic drink per week Prior history epilepsy seizure disorder Known hypersensitivity inhibitor raf kinase VEGFR2 Females childbearing potential Smoking &gt; 10 cigarettes/day equivalent Excessive consumption ( five 8oz . cups/day ) coffee caffeine Healthy Volunteer : Existing failure major organ system , medical disorder would impair subject 's ability complete study ( opinion investigator sponsor ) , eg history blood coagulation disorder Hematocrit value &lt; 34 % control group screen Renal Impairment Groups : Existing failure major organ system medical disorder ( target disease ) would impair subject 's ability complete study ( opinion investigator sponsor ) Concomitant Medication : Renal impairment subject take phosphate binder , ion exchange resins and/or iron supplement may take meal , must withhold morning Day 1 ( dose day ) 4 hour postdose test procedure perform . Myocardial infarction , coronary artery bypass graft percutaneous transluminal coronary angiography within 6 month Day 1 ; unstable angina ; uncontrolled significant hypertension within 3 month Day 1 ; cerebral vascular accident transient ischemic attack within 12 month Day 1 Subjects hypertension medication dose change within one week Day 1 Subjects require dialysis Subjects kidney transplant Liver transaminase ( AST , ALT ) great 5 time ULN screening ; active liver disease unexplained persistent elevation liver function test Hematocrit value &lt; 24 % renal impaired group</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>